MRI end-points for clinical trials in ataxias: recommendations from the Ataxia Global Initiative MRI Biomarkers Working Group
4d ago1 min readNews
From the article
MRI end-point recommendations for ataxia trials from the Ataxia Global Initiative pave the way for effective disease-modifying therapies! Key focus: pre-symptomatic biomarker identification. PMID:42236987, Nat Rev Neurol 2026, @NatRevNeurol #Medsky #RNA 🧪
Continue reading on doi.orgYou might also wanna read
Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxia (FA)
clinicaltrials.gov·7d ago
A Study to Evaluate Luspatercept Utilization in Patients With Lower Risk Myelodysplastic Syndromes or Beta-thalassemia
clinicaltrials.gov·7d ago
New MRI-Based Biomarker Predicts Aging and Disease Risks
Researchers from Duke University, Harvard University, and the University of Otago have developed DunedinPACNI, a noninvasive MRI-based bioma
insideprecisionmedicine.com·11mo agoBiophysical Assessments of Acupuncture Points in Inflammatory Bowel Disease
clinicaltrials.gov·7d ago
Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
clinicaltrials.gov·7d ago
Riptylimab for the Treatment of Optic Neuritis and Myelitis Spectrum Diseases
clinicaltrials.gov·3d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.